LUT TAMAM, Necla KESKİN

Paliperidone-Related Gynecomastia and Treatment: a Case Report

Paliperidon ile ilişkili jinekomasti ve tedavisi: Bir olgu sunumu Tipik antipsikotikler ve atipik antipsikotiklerden risperidon, amisülpirid ve paliperidonun sık görülen yan etkilerinden biri hiperprolaktinemidir. Hiperprolaktinemi ile ilişkili belirtiler erkek hastalarda kadınlara göre daha seyrek gelişmekte ve zaman zaman gözden kaçmaktadır. Antipsikotiklerin yol açtığı hiperprolaktineminin tedavisi hastaya özgü olmalıdır. Önerilen başlıca tedaviler; antipsikotik dozunun azaltılması, antipsikotiğin değiştirilmesi, tedaviye dopaminerjik agonist, seks steroidleri ya da aripiprazolün eklenmesidir. Bu yazıda paliperidon tedavisinin ikinci ayında jinekomasti ile başvuran bir olgu ve tedavisi tartışılmıştır.

Paliperidon ile ilişkili jinekomasti ve tedavisi: Bir olgu sunumu

Hyperprolactinemia is a frequent adverse effect of typical antipsychotics and atypical antipsychotics such as risperidone, amisulpride, and paliperidone. Side effects due to hyperprolactinemia are less frequent in males and sometimes these symptoms are overlooked. The management of a patient with antipsychoticinduced hyperprolactinemia must be patient specific. The recommended treatments include reducing dose of the offending antipsychotic, switching to another antipsychotic, using dopamine receptor agonist, adding sex steroids or aripiprazole to the treatment. In this report, a case that developed gynecomastia in the second month of the paliperidone treatment is presented, and its treatment is discussed

PDF

___

1. Yuksel N (editor). Basic Psychopharmacology. Ankara, Turkish Association of Psychiatry Publications, 2010, 767-866. (Turkish)
2. Bulut SD, Bulut S. Alatas E. Antipsychotic-induced Hyperprolactinemia. Current Approaches in Psychiatry 2015; 7:109-124. (Turkish)
3. Aboraya A, Fullen JE, Ponieman BL, Makela EH, Latocha M. Hyperprolactinemia associated with risperidone: a case report and review of literature. Psychiatry (Edgmont) 2004; 1:29-31.
4. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27:639-661. [CrossRef]
5. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28:421-453. [CrossRef]
6. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22(Suppl.):46-55. [CrossRef]
7. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64:2291-2314. [CrossRef]
8. Skopek M, Manoj P. Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry 2010; 18:261-263. [CrossRef]
9. Basterreche N, Zumárraga M, Arrue A, Olivas O, Dávila W. Aripiprazole reverses paliperidone-induced hyperprolactinemia. Actas Esp Psiquiatr 2012; 40:290-292.
10. Alpak G, Unal A, Bulbul F, Aksoy I, Demir B, Savas HA. Hyperprolactinemia due to paliperidone palmitate and treatment with aripiprazole. Bulletin of Clinical Psychopharmacology 2014; 24:253-256. [CrossRef]
11. Miyamoto BE, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatric Annals 2015; 45:266-272. [CrossRef]
12. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One 2013; 8:e70179. [CrossRef]
13. Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 2011; 74:141-147. [CrossRef]
14. Walters J, Jones I. Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol. 2008; 22(Suppl):82-89. [CrossRef]
15. Ucok A, Soygur H (editors). Schizophrenia Treatment Guide Updated Second Edition. Ankara, Turkish Psychiatric Association Publications, 2010, 106-108. (Turkish)